These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29339252)

  • 1. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
    J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
    Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
    Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
    Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
    Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
    Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
    de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
    J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
    Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
    Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
    Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells.
    Obara T; Kawano N; Tatsumi K; Katsuyama A; Nakajima K; Ogawa M; Ichikawa S
    Bioorg Med Chem; 2024 Jun; 108():117773. PubMed ID: 38850999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.